New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 633-637, 2021.
Article
de Zh
| WPRIM
| ID: wpr-880125
Bibliothèque responsable:
WPRO
ABSTRACT
Primary central nervous system lymphoma (PCNSL) is a rare aggressive non-Hodgkin's lymphoma outside the lymph nodes. At present, high-dose chemotherapy based on methotrexate is the standard induction therapy for newly diagnosed PCNSL, but the effective therapy of relapse/refractory and elderly PCNSL is still unclear. With the progress of clinical trials, new drugs and combined treatment method appear constantly, such as rituximab and ibrutinib, the remission rate of refractory and relapsed patients increased, while lenalidomide showed a good activity in the maintenance treatment of elderly patients. This review summarized briefly the recent advances of research on immunocheckpoint inhibitors, immunoregulatory agents, bruton tyrosine kinase (BTK) and PI3K/AKT/mTOR pathway inhibitors.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Lymphome malin non hodgkinien
/
Protocoles de polychimiothérapie antinéoplasique
/
Système nerveux central
/
Tumeurs du système nerveux central
/
Phosphatidylinositol 3-kinases
/
Récidive tumorale locale
Limites du sujet:
Aged
/
Humans
langue:
Zh
Texte intégral:
Journal of Experimental Hematology
Année:
2021
Type:
Article